Since the synergism between Aβ oligomers or plaques and pro-inflammatory factors could increase the neural damage to the brain,17 a combination therapy involving the inhibition of Aβ aggregation and NLRP3 inflammasome activation may enhance the therapeutic effect on AD. This evidence concerns the gene NLRP3 and Alzheimer disease.